Amphastar Pharmaceuticals
AMPH
28.25
+0.14
+0.50%
Amphastar Pharmaceuticals
US · AMPH
#3194 by market cap
28.25
+0.14
+0.50%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Maintains Target Price $30Market Newswire · 2026/2/25
-
Rating change
Wells Fargo Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Cuts Target Price to $30Market Newswire · 2026/2/27
-
Rating change
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold RatingMarket Newswire · 2026/7/9
-
Rating change
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI), Amphastar Pharmaceuticals (AMPH) and Amylyx Pharmaceuticals Inc (AMLX)TipRanks · 2026/5/8
-
Amphastar Pharmaceuticals (AMPH) Gets a Hold From J.P. MorganTipRanks · 2026/10/22
-
Rating change
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/4/15
-
Rating change
Needham Downgrades Amphastar Pharmaceuticals(AMPH.US) to Hold RatingMarket Newswire · 2026/5/8
-
Rating change
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $28Market Newswire · 2026/2/27
-
Rating change
Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20Market Newswire · 2026/6/4
-
Rating change
Wells Fargo Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Raises Target Price to $20Market Newswire · 2026/8/7
-
Rating change
Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $23Market Newswire · 2026/4/8
-
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $20Market Newswire · 2026/8/7
-
Rating change
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Cuts Target Price to $30Market Newswire · 2026/2/27
-
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Sell Rating, Raises Target Price to $23Market Newswire · 2026/11/7
-
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20Market Newswire · 2026/8/7
-
Rating change
Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $19Market Newswire · 2026/5/14
-
Rating change
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $21Market Newswire · 2026/5/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Ardent Health Partners, Inc. (ARDT) and Amphastar Pharmaceuticals (AMPH)TipRanks · 2026/6/3
-
Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Raises Target Price to $23Market Newswire · 2026/8/19
-
Rating change
BofA Securities Downgrades Amphastar Pharmaceuticals(AMPH.US) to Sell Rating, Cuts Target Price to $20Market Newswire · 2026/6/29
-
Rating change
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/2/25
-
Amphastar Pharmaceuticals (AMPH) Gets a Hold From J.P. MorganTipRanks · 2026/7/23
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.
Amphastar Pharmaceuticals discussion 0 comments